Literature DB >> 17081661

AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection.

Grant J Logan1, Lina Wang, Maolin Zheng, Sharon C Cunningham, Ross L Coppel, Ian E Alexander.   

Abstract

This study explores the utility of recombinant adeno-associated virus (rAAV) as a genetic vaccine delivery system using muscle as a target tissue. A single injection of rAAV encoding the malarial antigens MSP4 (Plasmodium falciparum) or MSP4/5 (Plasmodium yoelii) stimulated long-term antigen-specific antibody responses. Anti-MSP4/5 immunity stimulated by AAV was not protective against P. yoelii infection and efforts taken to augment antibody responses against MSP4/5, either by priming with plasmid DNA or AAV and boosting with rAAV were unsuccessful. Alternative strategies such as inclusion of genetic adjuvants into the AAV vector will be necessary to stimulate an adequate level of anti-malarial protective immunity in this model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081661     DOI: 10.1016/j.vaccine.2006.09.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 2.  The use of viral vectors in vaccine development.

Authors:  Tatianna Travieso; Jenny Li; Sneha Mahesh; Juliana Da Fonzeca Redenze E Mello; Maria Blasi
Journal:  NPJ Vaccines       Date:  2022-07-04       Impact factor: 9.399

3.  Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.

Authors:  Michelle J Boyle; Christine Langer; Jo-Anne Chan; Anthony N Hodder; Ross L Coppel; Robin F Anders; James G Beeson
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

4.  Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.

Authors:  Te-Hui Liu; Jon Oscherwitz; Bruce Schnepp; Jana Jacobs; Fen Yu; Kemp B Cease; Philip R Johnson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

5.  Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming.

Authors:  Yenni Yusuf; Tatsuya Yoshii; Mitsuhiro Iyori; Kunitaka Yoshida; Hiroaki Mizukami; Shinya Fukumoto; Daisuke S Yamamoto; Asrar Alam; Talha Bin Emran; Fitri Amelia; Ashekul Islam; Hiromu Otsuka; Eizo Takashima; Takafumi Tsuboi; Shigeto Yoshida
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 6.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

Review 7.  AAV Vectors Vaccines Against Infectious Diseases.

Authors:  Karen Nieto; Anna Salvetti
Journal:  Front Immunol       Date:  2014-01-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.